title: Dopamine D3 receptor in peripheral mononuclear cells of essential hypertensives.
abstract: Dopamine D3 receptor was studied in peripheral mononuclear cells of high-normal, stage 1, stage 2, and stage 3 essential hypertensives using a radioligand binding assay technique with [3H]-7-hydroxy-N,N-di-n-propyl-2-aminotetraline (7-OH-DPAT) as a radioligand. A group of de novo Parkinsonian patients was also examined as a reference group of impaired dopaminergic function. [3H]-7-OH-DPAT was bound specifically to human peripheral mononuclear cells in a manner consistent with the labeling of a dopamine D3 receptor. No changes in free dopamine, norepinephrine, epinephrine and aldosterone levels, renin activity, dissociation constant of [3H]-7-OH-DPAT binding, or the pharmacological profile of [3H]-7-OH-DPAT binding were found between normotensive control subjects and essential hypertensives or Parkinsonians. The density of peripheral mononuclear cell [3H]-7-OH-DPAT binding sites increased in essential hypertensives parallel to blood pressure value augmentation. A higher density of [3H]-7-OH-DPAT binding sites was found in Parkinsonians. In these patients, the density of [3H]-7-OH-DPAT binding sites was similar to that observed in high-normal subjects and in stage 1 essential hypertensives. The increased density of peripheral mononuclear cell dopamine D3 receptor in hypertension as well as in Parkinson's disease may represent an upregulation mechanism consequent to impaired dopaminergic function. In view of the difficulty in identifying markers of peripheral dopamine function, analysis of dopamine D3 receptor in peripheral mononuclear cells may help evaluate whether the dopaminergic system is involved in hypertension.
authors.affiliation: Department of Cardiovascular and Respiratory Sciences, University La Sapienza Rome, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Ricci
authors.forename: E
authors.initials: E
authors.lastname: Bronzetti
authors.forename: P
authors.initials: P
authors.lastname: Mulatero
authors.forename: M
authors.initials: M
authors.lastname: Schena
authors.forename: F
authors.initials: F
authors.lastname: Veglio
authors.forename: F
authors.initials: F
authors.lastname: Amenta
mesh_terms: D000328:Adult; D000450:Aldosterone / Q000097:blood; D001667:Binding, Competitive; D001794:Blood Pressure; D004298:Dopamine / Q000097:blood; D004837:Epinephrine / Q000097:blood; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000145:classification / Q000503:physiopathology; D007963:Leukocytes, Mononuclear / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009638:Norepinephrine / Q000097:blood; D011869:Radioligand Assay; D011954:Receptors, Dopamine / Q000097:blood; D017448:Receptors, Dopamine D2 / Q000097:blood*; D050637:Receptors, Dopamine D3; D012016:Reference Values; D012083:Renin / Q000097:blood; D013764:Tetrahydronaphthalenes / Q000097:blood
chemical_list: C493593:DRD3 protein, human; D011954:Receptors, Dopamine; D017448:Receptors, Dopamine D2; D050637:Receptors, Dopamine D3; D013764:Tetrahydronaphthalenes; D000450:Aldosterone; D012083:Renin; C031349:7-hydroxy-2-N,N-dipropylaminotetralin; D004298:Dopamine; D009638:Norepinephrine; D004837:Epinephrine